METHODS FOR THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA
Adult T-cell leukemia/lymphoma (ATL) is an aggressive proliferation of mature activated CD4+ T cells associated with the human T-cell lymphotropic virus type I (HTLV-I). The inventors performed an integrated genomic analysis of a retrospective cohort of 62 ATL patients mainly originating from Africa and the Caribbean area. In particular, they identified a subset of mutations in the TCR/NF-KB pathway (PLCG1, CARD11, PRKCB, CBLB, IRF4, CSNK1A1, FYN, RHOA, VAV1). Furthermore, the inventors investigated the effects of an anti-CD3 antibody (OKT3) exposure on 4 ATL samples including 2 cases harboring CARD 11 and PRKCB gain of function alterations and 2 cases without any TCR pathway mutation. The data suggest that ATL harboring TCR pathway mutations clearly responded to anti-CD3 (FIG. 1 B, red+OKT3) and died by apoptosis possibly by a mechanism resembling AICD. Importantly, these TCR-pathway/NFKB mutated patients also showed poorer outcome as compared to unmutated cases. Accordingly, the present invention relates to a method of treating adult T-cell leukemia/lymphoma (ATL) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-CD3 antibody.
1 . A method of treating adult T-cell leukemia/lymphoma (ATL) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-CD3 antibody.
2 . The method of claim 1 wherein the patient harbors at least one gain-of-function mutation in a gene involved in the TCR/NF-κB pathway.
3 . The method of claim 1 wherein the patient harbors at least one gain-of-function mutation in PLCG1, CARD11, PRKCB, CBLB, IRF4, CSNK1A1, FYN, RHOA, or VAV1.
4 . The method of claim 1 further comprising the steps of i) detecting the at least one gain-of-function mutation in a nucleic acid sample obtained from the patient and ii) administering to the patient the therapeutically effective amount of the anti-CD3 antibody when said at least one gain-of-function mutation is detected.
5 . The method of claim 1 wherein the anti-CD3 antibody is a chimeric antibody, a humanized antibody or a human antibody.
6 . The method of claim 1 wherein the anti-CD3 antibody is selected from the group consisting of foralumab, muromonab, otelixizumab, teplizumab and visilizumab.
7 . The method of claim 1 wherein the anti-CD3 antibody is muromonab having a light chain as set forth in SEQ ID NO:11 and a heavy chain as set forth in SEQ ID NO:12.
8 . The method of claim 1 wherein the anti-CD3 antibody is teplizumab having a light chain as set forth in SEQ ID NO:13 and a heavy chain as set forth in SEQ ID NO:14.
9 . The method of claim 1 wherein the anti-CD3 antibody is a non-mitogenic anti-CD3 antibody.
10 . The method of claim 1 wherein the anti-CD3 antibody is administered to the patient in combination with chemotherapy.
11 . The method of claim 3 , wherein the at least one gain-of-function mutation in PLCG1 is S345F, Q718K, DelEF730, G869F, S739T, Q916E, E1163K, R48W, D1165H, D1165E or DelDQ1169.
12 . The method of claim 3 , wherein the at least one gain-of-function mutation in CARD11 is D401N, R179W, R337Q, D401N, R423W, D357V, R377Q, R707C or E626.
13 . The method of claim 3 , wherein the at least one gain-of-function mutation in PRKCB is D427N, Q433K, A25V or D470H.
14 . The method of claim 3 , wherein the at least one gain-of-function mutation in CBLB is InsGH296.
15 . The method of claim 3 , wherein the at least one gain-of-function mutation in IRF4 is K59R, L70V, L64L, E109Q, S11R.
16 . The method of claim 3 , wherein the at least one gain-of-function mutation in CSNK1A1 is S189R or L160F.
17 . The method of claim 3 , wherein the at least one gain-of-function mutation in FYN is T15K or R206C).
18 . The method of claim 3 , wherein the at least one gain-of-function mutation in RHOA is C16Y, C16R, G17V, G124S, D120N, D120V, A161P or A161V.
19 . The method of claim 3 , wherein the at least one gain-of-function mutation in VAV1 is F69V, L145P, R195C, Q498K, M501L or N505T.